January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
July 2024 in “Reactions Weekly”
8 citations
,
October 2019 in “Dermatologic Therapy” Bicalutamide improves hair density in women safely.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
34 citations
,
April 1982 in “BMJ” 4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
August 2002 in “Inpharma Weekly”
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” Oral bicalutamide is safe and effective for female hair loss.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.